These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9273935)

  • 21. Changes of bone formation markers osteocalcin and bone-specific alkaline phosphatase in postmenopausal women with osteoporosis.
    Lumachi F; Ermani M; Camozzi V; Tombolan V; Luisetto G
    Ann N Y Acad Sci; 2009 Sep; 1173 Suppl 1():E60-3. PubMed ID: 19751416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
    Hansdóttir H; Franzson L; Prestwood K; Sigurdsson G
    J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normal bone, osteoporosis and the rheumatologist.
    Simon LS; Goodman T
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):3S-9S. PubMed ID: 9273930
    [No Abstract]   [Full Text] [Related]  

  • 24. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biochemical markers of bone turnover for treatment of osteoporosis].
    Fujiyama K; Kiriyama T
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():256-62. PubMed ID: 11979917
    [No Abstract]   [Full Text] [Related]  

  • 26. Relationship between BMD, dental panoramic radiographic findings and biochemical markers of bone turnover in diagnosis of osteoporosis.
    Vlasiadis KZ; Damilakis J; Velegrakis GA; Skouteris CA; Fragouli I; Goumenou A; Matalliotakis J; Koumantakis EE
    Maturitas; 2008 Mar; 59(3):226-33. PubMed ID: 18342460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basic science and clinical utility of biochemical markers of bone turnover--a Congress report.
    Seibel MJ; Baylink DJ; Farley JR; Epstein S; Yamauchi M; Eastell R; Pols HA; Raisz LG; Gundberg CM
    Exp Clin Endocrinol Diabetes; 1997; 105(3):125-33. PubMed ID: 9228507
    [No Abstract]   [Full Text] [Related]  

  • 28. [Biochemical markers of bone turnover. New aspect. An automated assay for measuring bone turnover markers].
    Miura M
    Clin Calcium; 2009 Aug; 19(8):1160-9. PubMed ID: 19638700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The clinical use of biological markers of bone turnover in postmenopausal osteoporosis].
    Delmas PD
    Ann Biol Clin (Paris); 2001; 59(3):299-308. PubMed ID: 11397679
    [No Abstract]   [Full Text] [Related]  

  • 30. Biochemical markers of bone turnover and bone mineral density in patients with beta-thalassaemia major.
    Eren E; Yilmaz N
    Int J Clin Pract; 2005 Jan; 59(1):46-51. PubMed ID: 15707464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biochemical markers of bone in steroid (glucocorticoid)-induced osteoporosis (GIOP)].
    Masaki H; Miki T
    Clin Calcium; 2006 Nov; 16(11):1823-32. PubMed ID: 17079849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of biochemical markers of bone turnover in Paget's disease of bone].
    Vignot E; Meunier PJ
    Ann Biol Clin (Paris); 2001; 59(3):309-11. PubMed ID: 11397680
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
    J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum prolidase activity in postmenopausal osteoporosis.
    Namiduru ES; Binnur Erbagci A; Celik A; Yilmaz M; Tarakçioglu M
    Minerva Med; 2007 Dec; 98(6):647-51. PubMed ID: 18299678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
    Bonnick SL; Shulman L
    Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis.
    Nawawi HM; Yazid TN; Ismail NM; Mohamad AR; Nirwana SI; Khalid BA
    Malays J Pathol; 2001 Dec; 23(2):79-88. PubMed ID: 12166596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.
    Delmas PD; Eastell R; Garnero P; Seibel MJ; Stepan J;
    Osteoporos Int; 2000; 11 Suppl 6():S2-17. PubMed ID: 11193237
    [No Abstract]   [Full Text] [Related]  

  • 39. [Biochemical markers of bone remodeling in the prevention of postmenopausal osteoporosis].
    Calleri L; Porcelli A; Surico N
    Minerva Ginecol; 1998 Oct; 50(10):423-8. PubMed ID: 9866953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
    Masaryk P; Stancíková M; Letkovská A; Rovenský J
    Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.